Skip to content

Developing a Childhood Asthma Risk Passive Digital Marker

Developing a Childhood Asthma Risk Passive Digital Marker

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05826561
Enrollment
34
Registered
2023-04-24
Start date
2024-06-01
Completion date
2025-06-16
Last updated
2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Asthma

Keywords

Pediatric Asthma, Early Detection, Screening, Passive Digital Marker, Risk Factors

Brief summary

Underdiagnosis and undertreatment is a major problem in childhood asthma management, especially in preschool-aged children. Current prognostic approaches using risk-score based tools have poor-to-modest accuracy, are impractical, and have limited evidence of efficacy in clinical settings and hence are not widely used in practice. The objective of the study is to determine the usability, acceptability, feasibility, and preliminary efficacy of the childhood asthma passive digital marker (PDM) among pediatricians. The study will include practicing pediatricians within the IU Health Network.

Interventions

OTHERChildhood Asthma Passive Digital Marker

A childhood asthma Passive Digital Marker (PDM) is an ML algorithm that is able to retrieve and synthesize pre-existing "passively" collected mother/child dyad prognostic data in "digital" electronic health record (EHR) to provide an objective and quantifiable "marker" of a child's risk (probability) and associated pathophysiological phenotype to inform clinician decision-making at point-of-care.

Sponsors

Indiana University
Lead SponsorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

• Practicing pediatricians within the IU Health Network

Exclusion criteria

• Non-practicing pediatricians within the IU Health Network

Design outcomes

Primary

MeasureTime frameDescription
Perceived PDM Acceptance8 to 12 monthsMean Perceived PDM acceptance measured using a Behavioral Intention scale (BIS) with a score Likert scale score of 0-5. Here, higher score values represent a higher acceptability of the PDM (i.e., better outcome).
Perceived PDM Usability8 to 12 monthsMean Perceived Usability measured using a modified Simplified System Usability Scale (SUS) with a score Likert scale of 0-5. Here, higher score values represent a higher perceived usability of the PDM (i.e., better outcome).
Study Feasibility8 to 12 monthsPercent of successful study enrollment of eligible clinicians (\>80%)

Secondary

MeasureTime frameDescription
Prognostic Accuracy3 to 12 monthsClinician prognostic accuracy was defined as the proportion of correctly classified vignettes. Accuracy was calculated as: correct vignette classifications ÷ total vignettes evaluated. Values ranged from 0 to 1, with higher values indicating greater prognostic accuracy. Each clinician assessed 10 vignettes (5 cases and 5 controls) and classified them as either high or low risk. A correct classification was high risk for a case and low risk for a control vignette.

Countries

United States

Participant flow

Recruitment details

Practicing pediatricians were recruited from clinics in Indiana over a 6-month recruitment period.

Pre-assignment details

Eligible participants were board-certified or board-eligible pediatricians providing outpatient pediatric care. No restrictions were applied regarding years of experience, practice setting, or demographic characteristics.

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
34 Participants
Race/Ethnicity, Customized
Count of White Participants
4 Participants
Region of Enrollment
United States
11 Participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 40 / 90 / 100 / 11
other
Total, other adverse events
0 / 40 / 90 / 100 / 11
serious
Total, serious adverse events
0 / 40 / 90 / 100 / 11

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026